| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 22, 2026 | HighLife Raises $90 Million To Start US Heart Valve Study and Grow in Europe | There are four valves in the heart that ensure blood flows correctly. The mitral valve is between the left chambers of the heart. When it is not properly closed up, blood leaks backward. Doctors describe this as mitral regurgitation.
To sol... |
| Sep 19, 2026 | Venture Capital Navigates Shifting Tides: Space, AI, and Biotech Secure Billions | Venture capital remains selective. Major funding rounds target critical sectors. Impulse Space secured $308M, valuing orbital logistics at $5.4B. AI innovators Arcee AI, Hang Ten, Noetive, Rune attracted significant capital. Biotech firm Sl... |
| Sep 16, 2026 | Venture Capital & Startup Funding Roundup, September 16, 2026: Andreessen Horowitz, Index Ventures, M12, Vista Equity & More | Venture capital is not moving evenly today. It is clustering around businesses that control a scarce input, remove an expensive operational bottleneck, or sit close enough to a measurable economic outcome that investors can underwrite somet... |
| Apr 7, 2026 | Route 92 Medical Receives $50M in Growth Financing | Route 92 Medical, Inc., a West Jordan, Utah-based medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, received $50m in growth financing.
New investor Sectoral Asset Management joine... |
| Oct 25, 2025 | SecondWave Systems: Series A Expanded To Advance Ultrasound-Based Anti-Inflammatory Therapy | SecondWave Systems, a clinical-stage medical device company pioneering ultrasound-based therapies for inflammatory diseases, has announced the addition of Sectoral Asset Management to its Series A investment syndicate. The expanded financin... |
| Oct 24, 2025 | SecondWave Systems Receives New Investment to Expanded Series A Funding | SecondWave Systems, Inc., a St. Paul, MN-based clinical stage medical device company developing a novel ultrasound-based treatment for inflammatory disorders, received a new investment to expand its Series A syndicate.
New investor Sectoral... |
| Aug 23, 2025 | Iantrek: $42 Million Series C Raised For Interventional Glaucoma Therapy | Iantrek, a leader in bio-interventional ophthalmic surgery (BIOS), has closed a $42 million Series C financing round. These funds will support the U.S. launch of AlloFlo Uveo, a novel surgical solution targeting the uveoscleral pathway, and... |
| Jul 14, 2025 | Breakthrough Funding Fuels Amputee Pain Revolution | Neuros Medical secured $56 million in Series D funding. EQT Life Sciences led the investment round. This substantial capital accelerates the U.S. commercialization of Altius®, a groundbreaking system. Altius® is FDA-approved. It delivers no... |
| Jul 9, 2025 | Neuros Medical Raises $56M in Series D Funding | Neuros Medical, Inc., an Aliso Viejo, CA-based maker of the Altius® Direct Electrical Nerve Stimulation System, an FDA-approved, breakthrough non-opioid treatment for chronic post-amputation pain, raised $56m in Series D financing round.
Th... |
| Nov 9, 2024 | Evommune Secures $115 Million to Tackle Chronic Inflammatory Diseases | In the bustling world of biotechnology, Evommune has made waves. The Palo Alto-based company recently secured $115 million in Series C financing. This funding is a lifeline, aimed at advancing their clinical-stage pipeline focused on immune... |
| Nov 8, 2024 | Evommune: $115 Million (Series C) Secured To Advance Clinical-Stage Pipeline Addressing Chronic Inflammatory Diseases | Evommune – a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases – announced the completion of a $115 million Series C financing. The funding was co-led by new investors RA... |
| Sep 19, 2024 | Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer | NAARDEN, The Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative dise... |
| Mar 12, 2024 | Prilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington’s Disease | NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)-- Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative disease... |
| Mar 12, 2024 | Prilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington’s Disease | -Following positive pre-submission meetings with regulators, Prilenia plans to submit its MAA for pridopidine in Huntington’s disease (HD) in mid-2024-
-If approved, pridopidine could be commercially available to patients in Europe as early... |
| Mar 4, 2024 | Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management | MANCHESTER, England, March 4, 2024 /PRNewswire/ -- Phagenesis, a pioneering UK company which has developed a revolutionary neurostimulation system to treat swallowing dysfunction, has closed a $42M Series D financing all equity investment r... |
| Jan 26, 2023 | Miach Orthopaedics Snags $40M to Change the Standard of Care for ACL Tears | Miach Orthopaedics — a medical device company focused on restoring torn anterior cruciate ligaments (ACLs) instead of reconstructing them — received $40 million in funding on Wednesday.
The financing includes $30 million in investments from... |
| Sep 16, 2021 | Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partners | LYON, France and CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has closed an $80... |
| Sep 16, 2021 | Andera Partners leads Amolyt Pharma’s $80 million Series B alongside Sectoral Asset Management | Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has closed an $80 million Series B equity financing round. The financing was co-led by ... |
| Jul 26, 2017 | New nonmetal cervical disc set to reduce radiation exposure for patients after surgery | Simplify enters a crowded replacement disc market.
However, the company is banking that its nonmetal discs will provide a significant competitive advantage. Metal discs create artifacts that can reduce MRI image quality, forcing clinicians ... |
| Feb 19, 2016 | Effector Therapeutics bumps up Series B to $56M | The company says that eFT508 can regulate a number of cancer-driving and immune-signaling pathways – designed to restore translational control to stop disease progression.
Promoted
Covid-19’s terrible toll on diabetes patients. What can be ... |
| Jul 22, 2014 | MoneyTree Reports $121M in MI Venture Deals Last Quarter | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Venture Capital investors had a very active second quarter of 2014, according to the latest MoneyTree report. VCs invested almost $13 billion in 1,114 U.S. startups during the... |
| Apr 22, 2014 | ProNAi Therapeutics Closes on $59.5M to Advance Cancer Drug | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
ProNAi Therapeutics, a Plymouth, MI-based developer of novel nucleic acid treatments targeting cancer and other genetic diseases, said this week that it has closed a Series D ... |
| Apr 21, 2014 | ProNAi raises $60 million to advance treatment to combat lymphoma | Among the applications for its PNT2258 treatment are diffuse large B-cell lymphoma, Richter’s transformation, and follicular lymphoma. The funds will also support drug manufacturing, advance development of preclinical drug candidates and th... |
| Nov 27, 2013 | Endosense closes CHF 37.4 million series C round | |
| Apr 29, 2013 | RainDance Technolgies raises $20M to grow market for DNA sequencing tools | The company’s core customers are genetic laboratories carrying out research for personalized drug development and diagnostics. Although it has traditionally been a laborious process to test different regions of the human genome, the company... |
| Effector Therapeutics bumps up Series B to $56M | San Diego-based Effector Therapeutics – which is developing a new class of small molecule drugs for cancer treatment – just added $16 million to its Series B round, first announced in December, bringing the total to $56 million. These drugs... |
| New nonmetal cervical disc set to reduce radiation exposure for patients after surgery | Australian company Simplify Medical recently raised $21 million in a Series B round to support two pivotal clinical trials and commercialize its polymer/ceramic cervical device in Europe. The investment was led by Life Sciences Partners and... |
| RainDance Technolgies raises $20M to grow market for DNA sequencing tools | It seems like many of the ongoing developments in genetic research share one thing in common: the need for speed. RainDance Technologies, a life science company with DNA sequencing tools to aid research and development for personalized ther... |
| ProNAi raises $60 million to advance treatment to combat lymphoma | Cancer drug developer ProNAi Therapeutics, which developed a nucleic acid-based DNA-interference technology to cause cancer cell death, has added nine new investors in an oversubscribed Series D round.
The latest fundraise will help support... |
